SCHEMBL4866643

SCHEMBL4866643

O=C(CCl)Nc1ccc(Cl)c2ccccc12

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 10/20 0.51
LMNA P02545 4/20 0.51
HTT P42858 4/20 0.51
SMN1; SMN2 Q16637 3/20 0.51
MAPT P10636 1/20 0.48
BLM P54132 2/20 0.47
NPSR1 Q6W5P4 2/20 0.47
NOD2 Q9HC29 1/20 0.47
KMT2A Q03164 6/20 0.46
MEN1 O00255 5/20 0.46
CYP1A2 P05177 1/20 0.45
CYP2A6 P11509 1/20 0.45
NPC1 O15118 1/20 0.45
MITF O75030 1/20 0.45
RAB9A P51151 1/20 0.45
ATM Q13315 1/20 0.43
EP300 Q09472 1/20 0.42
TEAD1 P28347 1/20 0.42
YAP1 P46937 1/20 0.42
TEAD4 Q15561 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2680971 0.83 EP300 (0.60) ALDH1A1LMNAHTTSMN1; SMN2BLM
SCHEMBL7912442 0.80 CYP1A2 (0.50) LMNAKMT2ACYP1A2CYP2A6NPC1
SCHEMBL8027426 0.79 EP300 (0.47) ALDH1A1LMNAHTTSMN1; SMN2MAPT
SCHEMBL14444101 0.79 RXFP1 (0.64) ALDH1A1MAPTKMT2AMEN1CYP1A2
SCHEMBL1272337 0.78 KMT2A (0.70) ALDH1A1LMNAHTTBLMNPSR1
SCHEMBL29728210 0.77 MAPT (0.68) ALDH1A1LMNAHTTSMN1; SMN2MAPT
SCHEMBL4867099 0.77 MAPT (0.68) ALDH1A1LMNAHTTSMN1; SMN2MAPT
SCHEMBL4011016 0.77 ALDH1A1 (0.65) ALDH1A1LMNAHTTSMN1; SMN2MAPT
SCHEMBL6054969 0.76 NPC1 (0.60) ALDH1A1MAPTNPSR1KMT2AMEN1
SCHEMBL8028208 0.76 ALDH1A1 (0.59) ALDH1A1LMNAHTTSMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7407960-B2 Substituted heterocyclic compounds CV THERAPEUTICS, INC. (US) 2008-08-05 US disclosed
EP-1806346-A1 Substituted piperazine compounds and their use as fatty acid oxidation inhibitors CV THERAPEUTICS, INC. (US) 2007-07-11 EP disclosed
US-20070004751-A1 Substituted heterocyclic compounds ELZEIN ELFATIH 2007-01-04 US disclosed
US-7125876-B2 Substituted heterocyclic compounds CV THERAPEUTICS, INC. (US) 2006-10-24 US disclosed
EP-1567525-A2 SUBSTITUTED PIPERAZINE COMPOUNDS AND THEIR USE AS FATTY ACID OXIDATION INHIBITORS CV THERAPEUTICS, INC. (US) 2005-08-31 EP disclosed
US-20040152890-A1 Substituted heterocyclic compounds CV THERAPEUTICS, INC. 2004-08-05 US disclosed
WO-2004052887-A2 SUBSTITUTED PIPERAZINE COMPOUNDS AND THEIR USE AS FATTY ACID OXIDATION INHIBITORS CV THERAPEUTICS, INC. (US) 2004-06-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152890-A1 Substituted heterocyclic compounds KCNH1, SDHA, COQ8A ALDH1A1 245/4885LMNA 2835/4885HTT 2557/4885
US-20070004751-A1 Substituted heterocyclic compounds KCNH1, SDHA, COQ8A ALDH1A1 281/4885LMNA 2300/4885HTT 2259/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.